Statistics

Total Visits

Views
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study64

Select a period of time:

Number of views in the range

Views
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study32

Views

Views
December 20253
January 20262
February 20261
March 20264
April 20261
May 202613
June 20268
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States11
Netherlands5
Finland4
Ecuador2
Côte d'Ivoire1
Chile1
Germany1
Egypt1
Spain1
France1
 

Top cities views

Views
Groningen5
Helsinki4
Caaguazú1
Council Bluffs1
Fortville1
Frankfurt am Main1
Madrid1
Manta1
New Cairo1
Oujda1